Patents by Inventor Milton Brown

Milton Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Coupling method
    Patent number: 11959135
    Abstract: The invention relates to a new method of determining the presence, absence or characteristics of an analyte. The analyte is coupled to a membrane. The invention also relates to nucleic acid sequencing.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: April 16, 2024
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: James Anthony Clarke, James White, John Milton, Clive Gavin Brown
  • Coupling method
    Patent number: 11946102
    Abstract: The invention relates to a new method of determining the presence, absence or characteristics of an analyte. The analyte is coupled to a membrane. The invention also relates to nucleic acid sequencing.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: April 2, 2024
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: James Anthony Clarke, James White, John Milton, Clive Gavin Brown
  • Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation
    Publication number: 20230302034
    Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
    Type: Application
    Filed: April 2, 2023
    Publication date: September 28, 2023
    Inventors: Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
  • Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
    Patent number: 11654157
    Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: May 23, 2023
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
  • Selective histone deacetylase inhibitors for the treatment of human disease
    Patent number: 11584733
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: February 21, 2023
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE
    Publication number: 20220348551
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 3, 2022
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20220055988
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Application
    Filed: September 24, 2021
    Publication date: February 24, 2022
    Inventors: Scott GRINDROD, Mira JUNG, Milton BROWN, Anatoly DRITSCHILO
  • SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE
    Publication number: 20210261523
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Application
    Filed: May 10, 2021
    Publication date: August 26, 2021
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Selective histone deacetylase inhibitors for the treatment of human disease
    Patent number: 11034667
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: June 15, 2021
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20200317611
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Scott GRINDROD, Mira JUNG, Milton BROWN, Anatoly DRITSCHILO
  • Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
    Patent number: 10745352
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: August 18, 2020
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
    Patent number: 10730834
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 4, 2020
    Assignee: Shuttle Pharmaceuticals, Inc.
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE
    Publication number: 20200071288
    Abstract: Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
    Type: Application
    Filed: January 9, 2018
    Publication date: March 5, 2020
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation
    Publication number: 20190343859
    Abstract: Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 14, 2019
    Inventors: Scott Grindrod, Mira Jung, Olga Timofeeva, Milton Brown, Anatoly Dritschilo
  • Radioprotector compounds
    Patent number: 10266490
    Abstract: Radioprotector compounds including 3,3?-diindolylmethane (DIM) analogs, are provided. Further provided are methods for their use in reducing or preventing radiation damage, killing a tumor cell and protecting a non-tumor cell, and treating cancer.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 23, 2019
    Assignee: Georgetown University
    Inventors: Eliot M. Rosen, Milton Brown, Saijun Fan, Thomas Walls, Kathryn E. Ditmer
  • Compounds and methods of use thereof for treating tumors
    Patent number: 10160716
    Abstract: The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated with abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 25, 2018
    Assignee: Georgetown University
    Inventors: Eliot M. Rosen, York A. Tomita, Milton Brown
  • Compounds and Methods of Use Thereof for Treating Tumors
    Publication number: 20180148401
    Abstract: The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated with abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 31, 2018
    Inventors: Eliot M. Rosen, York A. Tomita, Milton Brown
  • DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20180057456
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Inventors: Scott GRINDROD, Mira JUNG, Milton BROWN, Anatoly DRITSCHILO
  • DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20180044292
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 15, 2018
    Inventors: Scott GRINDROD, Mira JUNG, Milton BROWN, Anatoly DRITSCHILO
  • Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
    Patent number: 9809539
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: November 7, 2017
    Assignee: Shuttle Pharmaceuticals, LLC
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo